Related Experiment Video
Updated: Oct 11, 2025

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
[Clinical characteristics and gene analysis of SYNGAP1-related epilepsy in children]
1Department of Neurology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
Insights
SYNGAP1-related epilepsy in children presents with early-onset seizures, predominantly eyelid myoclonia, and often includes developmental delays. Valproate shows effectiveness, though some cases remain intractable.
Area of Science:
- Pediatric Neurology
- Clinical Genetics
- Epileptology
Background:
- SYNGAP1 gene variants are increasingly recognized as a cause of developmental and epileptic encephalopathies.
- Understanding the specific clinical phenotype associated with SYNGAP1 mutations is crucial for diagnosis and management.
Purpose of the Study:
- To delineate the clinical characteristics, seizure types, EEG findings, and treatment responses in children with SYNGAP1-related epilepsy.
- To evaluate the efficacy of antiepileptic drugs, particularly valproate, in this patient cohort.
Main Methods:
- Retrospective analysis of clinical data from 13 pediatric patients with genetically confirmed SYNGAP1 epilepsy.
- Review of seizure types, electroencephalogram (EEG) findings, neuroimaging, genetic variants, and treatment outcomes.
- Follow-up data collected over a defined period to assess seizure control and developmental progress.
Main Results:
- Early seizure onset (median 2 years) with diverse seizure types, including eyelid myoclonia with absence, myoclonic, and atypical absence seizures.
- Developmental retardation, primarily affecting speech, was present in all patients (moderate to severe in most).
- Valproate demonstrated significant efficacy in 9 out of 12 treated patients, while levetiracetam showed partial effectiveness in 3 out of 5 cases.
Conclusions:
- SYNGAP1-related epilepsy is characterized by early onset, varied seizure semiologies, and significant developmental impairment, particularly speech delay.
- Valproate is an effective first-line treatment for many, but intractable epilepsy can occur.
- Genetic testing for SYNGAP1 variants is important for children with unexplained early-onset epilepsy and developmental delay.
Abstract:
Objective: To summarize the clinical characteristics of SYNGAP1-related epilepsy in children. Methods: Data of 13 patients with SYNGAP1 gene variants diagnosed with epilepsy at Department of Neurology, Beijing Children's Hospital were collected retrospectively from March 2017 to October 2020 and the patients were followed up. The clinical features, electroencephalogram(EEG), brain imaging, gene results and treatment were summarized. Results: Twelve patients were followed up successfully among the 13 patients with SYNGAP1 variants. The last follow-up age was 5 years and 7 months (3 years and 1 month to 9 years).The onset age of seizures was 2 years (4 months to 3 years). Seizure types included eyelid myoclonia with or without absence (9 cases), myoclonic seizure (5 cases), atypical absence (4 cases), suspicious atonic seizures(4 cases),unclassified fall attack (6 cases), and the frequency of seizures varied from several times to more than 100 times per day. Four cases had the mimic phenotype of myoclonic astatic epilepsy. The seizures of 10 cases could be triggered by eating (5 cases), emotion (5 cases), fever (3 cases), voice (2 cases), fatigue (2 cases), etc. Electroencephalography (10 cases) showed interictal generalized or focal epileptiform discharges (9 cases), and atypical aphasia (4 cases), myoclonic seizure (2 cases) and eyelid myoclonic seizure (1 case) were monitored. Of the 12 cases, 9 were added with valproate, all of which were effective (the frequency of seizures reduced>50%). Five cases received combined levetiracetam, in 3 the treatments were effective. To last follow-up, 3 cases were seizure free from 6 months to 1 year and 1 month, but the remaining 7 cases still had seizures, one or several times per day. All 13 cases had developmental retardation (speech ability impaired mostly), 2 cases were severe, 10 cases were moderate, 1 case was mild. The SYNGAP1 gene variants of 13 patients were all de novo, including 12 variants. Among them, 4 were frameshift variants, 4 were nonsense variants, 2 were missense variants and 2 were splice site variants. Conclusions: Patients with SYNGAP1-related epilepsy have an early onset age and many seizure types. The main seizure type is eyelid myoclonia with or without absence, and other seizure types include myoclonic seizure, atypical absence, unclassified fall attack, etc. Valproate is effective in most patients, but seizures in some patients might be intractable. Most patients have developmental delay (mainly moderate and severe), speech ability impaired mostly.
More Related Videos
06:58A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy
Published on: July 12, 2021
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types: